Vaccine Peer Review : 1915-2015, The History of the Global Vaccination Program in 1000 Peer Reviewed Reports and Studies 1915-2015

By Prager, Jeffrey, J.

Book Id: WPLBN0100003171
Format Type: PDF eBook:
File Size: 5.72 MB
Reproduction Date: 4/5/2015

Title:	Vaccine Peer Review : 1915-2015, The History of the Global Vaccination Program in 1000 Peer Reviewed Reports and Studies 1915-2015
Author:	Prager, Jeffrey, J.
Volume:
Language:	English
Subject:	Non Fiction, General Works (Periodicals, Series, idexes, Almanacs, etc.), History of vaccination and vaccine ingredients
Collections:	Authors Community, Medicine
Historic Publication Date:	2015
Publisher:	Self-published

Member Page:	Jeff Prager
Citation APA MLA Chicago J. Prage, B. J. (2015). Vaccine Peer Review : 1915-2015, The History of the Global Vaccination Program in 1000 Peer Reviewed Reports and Studies 1915-2015. Retrieved from http://gutenberg.cc/

Description
The history of the global vaccination program in 1000+ peer reviewed reports and studies chronologically ordered and chaptered providing the reader with an understanding of disease outbreak, vaccine efficacy, the historic development of vaccines, unwanted contaminants, vaccine production methodology and more.

Summary
1,000 peer reviewed reports and studies across 1,053 pages, dated 1915 through the first quarter of 2016 with active hyper links to the original documents describing the development and application of vaccination to the human and feed-animal populations including positive effects, efficacy, unwanted effects and epigenetics.

Excerpt
INTRODUCTION (Excerpt) Over the past 35 years, patients have suffered from a largely hidden epidemic of side effects from drugs that usually have few offsetting benefits. The pharmaceutical industry has corrupted the practice of medicine through its influence over what drugs are developed, how they are tested, and how medical knowledge is created. Since 1906, heavy commercial influence has compromised Congressional legislation to protect the public from unsafe drugs. The authorization of user fees in 1992 has turned drug companies into the FDA’s prime clients, deepening the regulatory and cultural capture of the agency. Industry has demanded shorter average review times and, with less time to thoroughly review evidence, increased hospitalizations and deaths have resulted. Meeting the needs of the drug companies has taken priority over meeting the needs of patients. Unless this corruption of regulatory intent is reversed, the situation will continue to deteriorate. We offer practical suggestions including: separating the funding of clinical trials from their conduct, analysis, and publication: independent FDA leadership; full public funding for all FDA activities; measures to discourage R&D on drugs with few if any new clinical benefits; and the creation of a National Drug Safety Board. Institutional corruption is a normative concept of growing importance that embodies the systemic dependencies and informal practices that distort an institution’s societal mission. An extensive range of studies and lawsuits already documents strategies by which pharmaceutical companies hide, ignore, or misrepresent evidence about new drugs; distort the medical literature; and misrepresent products to prescribing physicians. We focus on the consequences for patients: millions of adverse reactions. After defining institutional corruption, we focus on evidence that it lies behind the epidemic of harms and the paucity of benefits. It is our thesis that institutional corruption has occurred at three levels. First, through large-scale lobbying and political contributions, the pharmaceutical industry has influenced Congress to pass legislation that has compromised the mission of the Food and Drug Administration (FDA). Second, largely as a result of industry pressure, Congress has underfunded FDA enforcement capacities since 1906, and turning to industry-paid “user fees” since 1992 has biased funding to limit the FDA’s ability to protect the public from serious adverse reactions to drugs that have few offsetting advantages. Finally, industry has commercialized the role of physicians and undermined their position as independent, trusted advisers to patients. Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs Authors: Donald W. Light, Ph.D., is a fellow for 2012-2013 at the Edmond J. Safra Center for Ethics at Harvard University in Cambridge, MA. He received his Ph.D. in sociology from Brandeis University and is a professor of comparative health policy at Rowan University, School of Osteopathic Medicine. Jonathan J. Darrow, J.D., M.B.A., LL.M., S.J.D., is a research fellow at Harvard Medical School and a lecturer on law at Bentley University in Waltham, MA. He received his S.J.D. from Harvard in 2013. Joel Lexchin, M.Sc., M.D., has been teaching health policy for 12 years at York University in Toronto, ON. He received his M.D. from the University of Toronto in 1977 and since 1988 has been an emergency physician at the University Health Network in Toronto. ~ June 1, 2013 ~ Journal of Law, Medicine and Ethics, 2013, Vol. 14, No. 3:590-610

Table of Contents
Table of Contents 1. Manufacturing Biologics Thimerosal • Mercury 2. Alum • Aluminum Salts 3. The HPV Vaccine 4. Vaccination History 1915 - 2015 5. Short Essays On Vaccination